News >

Pembrolizumab Misses OS Endpoint in Metastatic TNBC

Gina Columbus @ginacolumbusonc
Published: Monday, May 20, 2019

Dr. Roy Baynes

Roy Baynes, MD, PhD
Single-agent pembrolizumab (Keytruda) did not meet a prespecified endpoint of superior overall survival (OS) compared with chemotherapy as a second- or third-line treatment for patients with metastatic triple-negative breast cancer (TNBC), missing the primary endpoint of the phase III KEYNOTE-119 trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication
x